Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 44M | 33M | 20M | 17M | 13M |
| Gross Profit | 33M | 25M | 14M | 12M | 8M |
| Operating Income | 5M | 5M | -540K | -9M | -14M |
| EBITDA | 6M | -17M | -9M | 5M | -19M |
| Net Income | 12M | -31M | -26M | -10M | -27M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$9.21
+1.32% today
1Y Change
-55.59%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SANUWAVE Health, Inc. (SNWV) is a Healthcare stock with a market cap of $140.00M and listed on NASDAQ. The stock last traded around $9.21 and down 55.6% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +35.0%, EPS growth of +119.6%, a dividend yield of 0.0%. What stands out right now is revenue +35.0%, EPS +119.6%, free cash flow -1.6% with operating margin 11.2% and ROIC 19.4%. Valuation is more restrained than many high-expectation growth names at P/E 11.4 and price/sales 3.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SNWV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNWV
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SNWV Max Drawdown
-68.04%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SNWV and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$13.0M
-22.3% YoY
FY Net Income
-$27.3M
-164.8% YoY
Free Cash Flow
-$6.9M
+57.0% YoY
Revenue Growth
+35.0%
EPS Growth
+119.6%
Gross Margin
75.1%
Net Margin
26.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 44M | 33M | 20M | 17M | 13M |
| Gross Profit | 33M | 25M | 14M | 12M | 8M |
| Operating Income | 5M | 5M | -540K | -9M | -14M |
| EBITDA | 6M | -17M | -9M | 5M | -19M |
| Net Income | 12M | -31M | -26M | -10M | -27M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12M | 10M | 2M | 1M | 619K |
| Total Assets | 37M | 30M | 22M | 20M | 19M |
| Total Liabilities | 36M | 43M | 66M | 61M | 58M |
| Shareholder Equity | 2M | -13M | -43M | -41M | -39M |
| Total Debt | 23M | 25M | 30M | 39M | 28M |
| Net Debt | 11M | 15M | 29M | 38M | 28M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
6M
+62.7% YoY
Capital Expenditures
529K
-151.8% YoY
Free Cash Flow
7M
+57.0% YoY
Key ratios
Gross Margin
75.1%
Operating Margin
11.2%
Net Margin
26.8%
ROE
-141.6%
Debt / Equity
14.19x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.